UY40407A - Moléculas de unión al antígeno alfavirus y usos de las mismas - Google Patents

Moléculas de unión al antígeno alfavirus y usos de las mismas

Info

Publication number
UY40407A
UY40407A UY0001040407A UY40407A UY40407A UY 40407 A UY40407 A UY 40407A UY 0001040407 A UY0001040407 A UY 0001040407A UY 40407 A UY40407 A UY 40407A UY 40407 A UY40407 A UY 40407A
Authority
UY
Uruguay
Prior art keywords
alfavirus
antigen
binding molecules
cdr
seq
Prior art date
Application number
UY0001040407A
Other languages
English (en)
Inventor
Michael Diamond
Saravanan Raju
Lucas Adams
Daved Fremont
Lo Vang
Original Assignee
Washington University St Louis
Emergent Travel Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University St Louis, Emergent Travel Health Inc filed Critical Washington University St Louis
Publication of UY40407A publication Critical patent/UY40407A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Molécula de unión a alfavirus que comprende las CDR-H1-H3 que comprenden las SEQ ID NO:2-4, 10-12, 18-20, 26-28, 34-36, 42-44, 50-52, 58-60, 66-68, 74-76, 82-94, 90-92, 98-100, 106-108, 114-116, 122-124, 130-132, 138-140, 146-148, 154-156, 162-164, 170-172, 178-180, 186-188, 194-196, 202-204, 210-212, 218-220, 226-228, 234-236, 242-244, 250-252, 258-260, 266-268, 274-276, 282-284, 290-292 o 298-300; y las CDR-L1-L3 que comprenden las SEQ ID NO:6-8, 14-16, 22-24, 30-32, 38-40, 46-48, 54-56, 62-64, 70-72, 78-80, 86-88, 94-96, 102-104, 110-112, 118-120, 126-128, 134-136, 142-144, 150-152, 158-160, 166-168, 174-176, 182-184, 190-192, 198-200, 206-208, 214-216, 222-224, 230-232, 238-240, 246-248, 254-256, 262-264, 270-272, 278-280, 286-288, 294-296 o 302-304.
UY0001040407A 2022-08-31 2023-08-29 Moléculas de unión al antígeno alfavirus y usos de las mismas UY40407A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263402559P 2022-08-31 2022-08-31

Publications (1)

Publication Number Publication Date
UY40407A true UY40407A (es) 2024-03-15

Family

ID=88188750

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001040407A UY40407A (es) 2022-08-31 2023-08-29 Moléculas de unión al antígeno alfavirus y usos de las mismas

Country Status (7)

Country Link
US (1) US20260062466A1 (es)
EP (1) EP4580753A1 (es)
AR (1) AR130358A1 (es)
CA (1) CA3264339A1 (es)
TW (1) TW202423964A (es)
UY (1) UY40407A (es)
WO (1) WO2024050354A1 (es)

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
ES2374068T3 (es) 2002-12-03 2012-02-13 Ucb Pharma, S.A. Ensayo para identificar células productoras de anticuerpos.
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
WO2011008609A1 (en) 2009-07-14 2011-01-20 Wavetec Vision Systems, Inc. Ophthalmic surgery measurement system
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
US12186383B2 (en) * 2018-06-06 2025-01-07 Albert Einstein College Of Medicine Antibodies or antibody-fragments thereof targeting alphaviruses, and compositions and methods comprising same
WO2021042021A1 (en) * 2019-08-31 2021-03-04 Vanderbilt University Human antibodies to alphaviruses
US20250320277A1 (en) * 2020-09-15 2025-10-16 Albert Einstein College Of Medicine Antibodies or antibody-fragments thereof targeting alphaviruses, and compositions and methods comprising same

Also Published As

Publication number Publication date
WO2024050354A1 (en) 2024-03-07
CA3264339A1 (en) 2024-03-07
US20260062466A1 (en) 2026-03-05
AR130358A1 (es) 2024-11-27
EP4580753A1 (en) 2025-07-09
TW202423964A (zh) 2024-06-16

Similar Documents

Publication Publication Date Title
Gamer et al. A cycle of binding and release of the DnaK, DnaJ and GrpE chaperones regulates activity of the Escherichia coli heat shock transcription factor sigma32.
Hengge-Aronis Interplay of global regulators and cell physiology in the general stress response of Escherichia coli
UY40407A (es) Moléculas de unión al antígeno alfavirus y usos de las mismas
ES2165843T3 (es) Moleculas de union al tgf-beta-1 similar al receptor, sustancialmente puras, y usos de las mismas.
BRPI0407175A (pt) Compostos de arilpiperazinila
AR001021A1 (es) Derivados de pirazol-4-il-benzoilo, procedimiento para prepararlos, composiciones herbicidas formuladas con dichos derivados y procedimiento paracombatir el crecimiento de plantas indeseables con aplicacion de dichos derivados.
AR119790A1 (es) Compuestos de isoxazolina y su uso como agentes para el control de plagas
AR091185A1 (es) Derivados de 1,2,4-triazol
Frasinyuk et al. Synthesis and tautomerization of hydroxylated isoflavones bearing heterocyclic hemi-aminals
CR20240493A (es) Proteínas de fusión de hmpv de prefusión estabilizadas
Capasso et al. Unveiling a VEGF-mimetic peptide sequence in the IQGAP1 protein
Phillips et al. SRY and human sex determination: the basic tail of the HMG box functions as a kinetic clamp to augment DNA bending
CN104230826B (zh) 2‑氟代喹唑啉环类化合物及其制备方法和药用用途
Tanaka et al. Light-induced conformational change and transient dissociation reaction of the BLUF photoreceptor Synechocystis PixD (Slr1694)
BR0009389A (pt) Benzoilpirazóis substituìdos como herbicidas
Lugo et al. Purification and characterization of Pseudomonas aeruginosa LasR expressed in acyl-homoserine lactone free Escherichia coli cultures
Rombouts et al. Intramolecular Diels–Alder reactions of N-alkenyl-2 (1H)-pyrazinones: generation of a novel type of cis-1, 7-naphthyridine
Hanif et al. Heterologous secretory expression and characterization of dimerized bone morphogenetic protein 2 in Bacillus subtilis
Wang et al. The structural and functional role of the three tryptophan residues in Pin1
Kruzhilin et al. Diastereoselective synthesis of pyrimido [1, 2-a][1, 3, 5] triazines based on the Biginelli reaction
Ferreira et al. Functional EGF domain of the human neuregulin 1α produced in Escherichia coli with accurate disulfide bonds
Jo et al. A tryptophan-based assay method to search regulatory compounds for TCTP
Ali et al. Copper-catalysed regioselective S-alkylation and C–3 (H) activation of 4-hydroxydithiocoumarins and 4-hydroxy-2 H-chromene-2-thione: easy access to 4-methyl-3, 4-dihydrothiopyran derivatives
GB587936A (en) New quinazoline derivatives
Chan et al. Structural basis for the activity and allosteric control of diguanylate cyclase